Publications by authors named "Simon Low"

Claim this Profile
T
T-cell receptor/CD28-targeted immunotherapeutics selectively drive naive T-cell expansion to generate functional HIV-specific responses.
April L Mueller, Sara Lamcaj, Scott Garforth, Christopher Hiner, Darien Woodley, Simon Low

J Virol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells.
Ronald D Seidel, Zohra Merazga, Dharma Raj Thapa, Jonathan Soriano, Emily Spaulding, Simon Low

Sci Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Functional Na1.7-NaAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site.
Ramkumar Rajamani, Sophie Wu, Iyoncy Rodrigo, Mian Gao, Simon Low

Mol Pharmacol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR.
Javed A Khan, Daniel M Camac, Simon Low, Andrew J Tebben, David L Wensel

J Mol Biol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering.
Tracy Mitchell, Ginger Chao, Doree Sitkoff, Fred Lo, Hossain Monshizadegan, Simon Low

J Pharmacol Exp Ther· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying factors associated with performance in a mock CSA: perceptions from trainees and trainers from one deanery.
Simon Low, Zoë A Sheppard, Stephen Tomkins

Educ Prim Care· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.
Hu Liu, Cyrille Kuhn, Frederic Feru, Suzanne L Jacques, Gayatri D Deshmukh, Simon Low

Bioorg Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.
Haile Tecle, Frederic Feru, Hu Liu, Cyrille Kuhn, Glen Rennie, Simon Low

Chem Biol Drug Des· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selectivity-determining residues in Plk1.
Michael Kothe, Darcy Kohls, Simon Low, Rocco Coli, Glen R Rennie

Chem Biol Drug Des· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of the catalytic domain of human polo-like kinase 1.
Michael Kothe, Darcy Kohls, Simon Low, Rocco Coli, Alan C Cheng

Biochemistry· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
André Iffland, Darcy Kohls, Simon Low, Jing Luan, Yan Zhang

Biochemistry· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis